Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Erika Schneider, PhD

216.444.7915

Erika Schneider, Ph.D.

Appointed: 2006

Erika Schneider, PhD
Department: Diagnostic Radiology
Location: Cleveland Clinic Main Campus
Mail Code L10
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.7915
WorkFax:216.636.1733
Surgeon:
No
Treats:
Adults Only

Education & Fellowships

Fellowship - Cambridge University
Cambridge England
1986
Doctorate - University of California at Berkeley
Chemistry
Berkeley, CA USA
1985
Undergraduate - California State University, Long Beach
Chemistry
Long Beach, CA USA
1981

Awards & Honors

  • 1997  Whitney Award for Technical Achievement
  • 1996  Alumnus of the Year, CSULB School of Natural Sciences and Mathematics
  • 1986 - 1988 NATO/NSF Postdoctoral Fellow
  • 1985 - 1986  Oppenheimer Research Fellow
  • 1981  American Chemical Society / California State University Long Beach, Analytical Chemistry Award
  • 1980 - 1981  The Aerospace Corporation Work-Study Program, Research Fellow
  • 1980  SIGMA XI Fellow
  • 1979  Society of Applied Spectroscopy, Los Angeles Chapter, Undergraduate Research Award

Innovations & Patents

  • Chenard BL, Saltarelli MD, Schneider E, Field MJ, Menta. Prophylactic Use of N-Methyl-D-Aspartate (NMDA) Antagonists. Docket 20020072485, A1: 13 June 2002.
  • Watkins RD, Rohling KW, Schneider E. RF Driven Resistive Ablation System for Use in MRI-Guided Therapy. U.S. Patent No. 6,393,314, Issued 21 May 2002.
  • Schneider E. MR Imaging of Lesions and Detection of Malignant Tumors. U.S. Patent No. 6,310,477; Issued 30 October 2001.
  • Hardy CJ, Dumoulin CL, Schneider E. Arterial MRI with Chemical Shift Nulling. U.S. Patent No. 5,999,839; Issued 07 December 1999.
  • Schneider E, Rohling KW, Giaquinto RO. Image-Guided Breast Lesion Localization Device. U.S. Patent No. 5,855,554; Issued 05 January 1999.
  • Schneider E, Cline HE, Watkins RD, Hardy CJ, Washburn SS. Real Time In Vivo Measurement of Temperature Changes with NMR Imaging. U.S. Patent No. 5,711,300; Issued 27 January 1998.
  • Dumoulin CL, Schneider E. Methods for Magnetic Resonance Angiography Using In-Flow of Transverse Spin Magnetization. U.S. Patent No. 5,671,742; Issued 30 September 1997.
  • Schneider E. Method of Magnet Shimming. U.S. Patent No. 5,617,029; Issued 01 April 1997.
  • Schneider E, Linz AM, Repinski GA. Measurement of Geometric Distortion in Magnetic Resonance Images. U.S. Patent No. 5,545,995; Issued 13 August 1996.
  • Schneider E, Zang X, Hartley M. Correction of Geometric Distortion in MRI Phase and Phase Difference Images. U.S. Patent No. 5,498,963; Issued 12 March 1996.
  • Schneider E, Bernstein MA. MR Imaging with Rectangular Magnetization Transfer Pulse. U.S. Patent No. 5,339,035; Issued 16 August 1994.
  • Schneider E. Selective Imaging Among Three or More Chemical Species. U.S. Patent No. 5,321,359; Issued 14 June 1994.
  • Glover GH, Schneider E. Robust Decomposition of NMR Images by Chemical Species. U.S. Patent No. 5,225,781; Issued 06 July 1993. European Patent rights granted 08 August 1990.
  • Glover GH, Schneider E. Method for Rapid Magnet Shimming. U.S. Patent No. 5,168,232; Issued 01 December 1992.
  • Glover GH, SchneiderE. Method of Decomposing NMR Images by Chemical Species. U.S. Patent No. 5,144,235; Issued 01 September 1992. European Patent rights granted 08 August 1990.
  • Glover GH, Schneider E. Method for In Vivo Shimming. U.S. Patent No. 4,987,371; Issued 22 January 1991.

Memberships

  • 2000 – Present - American Society for Experimental NeuroTherapeutics
  • 1999 – Present - American Heart Association, American Stroke Association
  • 1998 – Present - Drug Information Association
  • 1992 - Present - American Association of Physicists in Medicine
  • 1989 - Present - (International) Society of Magnetic Resonance in Medicine

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 8/27/2014, Dr. Schneider has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Schneider receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Image IQ, Inc.
  • National Institutes of Health (NIH)

Royalty Payments. Dr. Schneider receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:

  • NitroSci Pharmaceuticals, LLC
  • SciTrials, L.L.C.

Equity. Dr. Schneider owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:

  • NitroSci Pharmaceuticals, LLC
  • SciTrials, L.L.C.

Fiduciary Role. Dr. Schneider serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:

  • NitroSci Pharmaceuticals, LLC
  • SciTrials, L.L.C.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English